Selectis Health (GBCS)
OTHER OTC:GBCS
Want to see GBCS full AI Analyst Report?
Top Page
Selectis Health
(OTC:GBCS)
Select Model
Select Model
Rating:43Neutral
Price Target:
$1.50
▼(-32.74% Downside)
Action:ReiteratedDate:11/19/25
The overall score of 43 for GBCS reflects significant financial instability as the primary concern, with negative profitability, high leverage, and weak cash flows weighing heavily. Technical indicators further support a bearish outlook with the stock below key moving averages. Valuation offers no positive offset due to unprofitability and lack of dividend yield.
Positive Factors
Revenue Growth
Despite financial challenges, the company demonstrates modest revenue growth, indicating potential for market expansion and product adoption.
Negative Factors
High Financial Leverage
Excessive leverage can strain financial stability, limiting the company's ability to invest in growth opportunities and weather economic downturns.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Despite financial challenges, the company demonstrates modest revenue growth, indicating potential for market expansion and product adoption.
Read all positive factors
Selectis Health (GBCS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$14.19M
Dividend YieldN/A
Average Volume (3M)1.62K
Price to Earnings (P/E)―
Beta (1Y)-0.61
Revenue Growth4.94%
EPS Growth56.95%
CountryUS
Employees616
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-0.80
Shares Outstanding3,067,059
10 Day Avg. Volume980
30 Day Avg. Volume1,620
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)-1.10
Price to Sales (P/S)0.17
P/FCF Ratio4.75
Enterprise Value/Market Cap2.70
Enterprise Value/Revenue0.92
Enterprise Value/Gross Profit4.67
Enterprise Value/Ebitda17.49
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Selectis Health Business Overview & Revenue Model
Company Description
Global Healthcare REIT, Inc. (the "Company" or "Global") was organized with the intent of operating as a real estate investment trust (REIT) for the purpose of investing in real estate and other assets related to the healthcare industry. The Compa...
How the Company Makes Money
Selectis Health generates revenue through multiple channels, primarily by selling software licenses for its EHR systems and subscription fees for its telemedicine and patient engagement platforms. Additionally, the company earns income from consul...
Selectis Health Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
20
Very Negative
Cash Flow
25
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 41.44M | 39.49M | 36.78M | 40.60M | 29.29M |
| Gross Profit | 6.73M | 9.13M | 5.41M | 10.74M | 7.81M |
| EBITDA | 2.19M | 1.19M | -7.29M | 1.51M | 1.00M |
| Net Income | -1.02M | -2.42M | -3.97M | -2.40M | -2.25M |
Balance Sheet | |||||
| Total Assets | 32.58M | 33.45M | 40.67M | 42.49M | 46.92M |
| Cash, Cash Equivalents and Short-Term Investments | 1.01M | 680.33K | 1.48M | 1.42M | 3.96M |
| Total Debt | 25.45M | 32.23M | 37.25M | 37.89M | 38.50M |
| Total Liabilities | 38.79M | 38.86M | 43.64M | 41.54M | 43.82M |
| Stockholders Equity | -6.21M | -5.41M | -2.96M | 952.84K | 3.10M |
Cash Flow | |||||
| Free Cash Flow | 1.44M | -1.86M | 506.86K | -527.51K | -790.50K |
| Operating Cash Flow | 1.88M | -1.82M | 536.67K | -305.15K | -270.93K |
| Investing Cash Flow | -443.61K | 2.45M | -29.80K | -222.36K | -519.58K |
| Financing Cash Flow | -976.69K | -1.54M | -618.74K | -1.85M | 1.61M |
Selectis Health Technical Analysis
Positive
2.23
Price Trends
3.77
Positive
2.95
Positive
2.57
Positive
Market Momentum
0.16
Positive
71.05
Negative
74.32
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GBCS, the sentiment is Positive. The current price of 2.23 is below the 20-day moving average (MA) of 4.25, below the 50-day MA of 3.77, and below the 200-day MA of 2.57, indicating a bullish trend. The MACD of 0.16 indicates Positive momentum. The RSI at 71.05 is Negative, neither overbought nor oversold. The STOCH value of 74.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GBCS.
Selectis Health Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $1.46B | 12.43 | 13.60% | ― | 6.46% | 72.30% | |
72 Outperform | $1.07B | 28.23 | 9.31% | ― | 36.31% | 18.03% | |
52 Neutral | $817.97M | -6.34 | -14.67% | ― | -8.49% | 35.03% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $8.85M | -5.59 | -8.75% | ― | -0.91% | -168.54% | |
43 Neutral | $14.19M | -6.73 | 13.38% | ― | 4.94% | 56.95% | |
43 Neutral | $404.43M | -0.16 | 5.89% | ― | -2.87% | ― |
* Healthcare Sector Average
GBCS
Selectis Health
4.55
2.55
127.50%
AMS
American Shared Hospital Services
1.45
-1.32
-47.65%
AMN
AMN Healthcare Services
20.47
0.05
0.24%
CYH
Community Health
2.84
0.08
2.90%
HCSG
Healthcare Services
21.41
6.89
47.45%
PNTG
Pennant Group
31.32
5.90
23.21%
Selectis Health Corporate Events
Business Operations and StrategyExecutive/Board Changes
Selectis Health Adds Experienced Leaders to Board of Directors
Positive
Jan 6, 2026
Effective January 1, 2026, Selectis Health, Inc. appointed Kent J. Lund and former CEO Lance Baller to its Board of Directors, signaling a strategic move to deepen the board’s expertise in legal, compliance, and capital markets. Lund, a vete...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.